Who are Illumina's decision-makers?
Illumina is led by Jacob Thaysen. Sellers should map decisions across the executive sponsor, business-unit owner, procurement, legal, security, privacy, compliance, finance, clinical or scientific stakeholders, and implementation owners.
- CEO
- Jacob Thaysen
- CFO/key exec
- Ankur Dhingra
- Founded
- 1998
- Employees
- 9,000+
- HQ
- San Diego, CA
- Status
- Nasdaq: ILMN
- Jacob ThaysenChief Executive OfficerCEO since 2023Leads Illumina's sequencing-platform reset after the GRAIL divestiture.
- Ankur DhingraChief Financial OfficerCFO since 2024Oversees finance, margin improvement, and investor planning.
- Steve BarnardChief Technology OfficerCTO in 2026Guides sequencing technology, informatics, and platform roadmaps.
- Susan TousiChief Commercial OfficerCommercial leader in 2026Leads commercial execution across clinical and research markets.
Who leads Illumina?
Illumina's leadership team combines enterprise healthcare operations, finance, R&D, clinical, product, technology, legal, manufacturing, and commercial roles. The CEO and CFO set capital priorities, while business-unit leaders decide which operational problems become funded initiatives.
Who actually makes buying decisions at Illumina?
Buying decisions usually start with a business-unit sponsor, then move through procurement, finance, legal, information security, privacy, compliance, quality, and implementation owners. Clinical, reimbursement, regulatory, or scientific stakeholders become essential whenever the purchase touches patient care, regulated data, clinical evidence, medical products, lab workflows, or payer/provider economics.
How is Illumina organized as it scales?
Illumina operates through product, therapeutic-area, regional, manufacturing, commercial, and corporate functions. That creates multiple entry points, but enterprise standards for security, privacy, compliance, contracting, vendor risk, and data governance can still control the final approval path.
As of June 2026.Sources:Illumina leadershipIllumina annual reports
Illumina — frequently asked questions
